Table 1.
Baseline Characteristics | All Patients, n=34 | Control, n=17 | Rituximab, n=17 | P Value |
---|---|---|---|---|
Age, yr | 40 (21–63) | 33 (21–59) | 43 (29–63) | 0.04 |
Sex, women, men | 9, 25 | 2, 15 | 7, 10 | 0.12 |
Weight, kg | 89.7 (57–120) | 92.3 (57–119) | 85.1 (61–120) | 0.46 |
Race | 0.07 | |||
White | 24 | 15 | 9 | 0.07 |
Black | 1 | 0 | 1 | 0.07 |
Asian/Pacific Islanders | 6 | 2 | 4 | 0.07 |
Hispanic/Latino | 3 | 0 | 3 | 0.07 |
Systolic BP | 121 (102–147) | 118 (102–147) | 124 (107–144) | 0.17 |
Diastolic BP | 78 (56–106) | 78 (56–106) | 81 (59–94) | 0.24 |
Creatinine, mg/dl | 1.4 (0.8–2.4) | 1.3 (0.8–2.4) | 1.7 (0.8–2.3) | 0.07 |
eGFR | 49 (30–122) | 61 (32–122) | 40 (30–78) | 0.02 |
24-h Proteinuria, g | 2.1 (0.6–5.3) | 1.7 (0.6–4.0) | 2.6 (0.9–5.3) | 0.09 |
Oxford pathology score, % | ||||
M0/M1 | 3/97 | 6/94 | 0/100 | 0.30 |
E0/E1 | 68/32 | 76/24 | 59/41 | 0.30 |
S0/S1 | 15/85 | 12/88 | 18/82 | 0.60 |
T0/T1/T2 | 56/41/3 | 53/47/0 | 65/29/6 | 0.30 |
Data presented as median and range.